VXL.V

Vaxil Bio Ltd. [VXL.V] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VXL.V Stock Summary

In the News

VXL.V Financial details

Company Rating
-
Market Cap
2.05M
Income
-453K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-7.56
Forward P/E
-
PEG
1.4
P/S
-
P/B
3.98
P/C
-
P/FCF
-6.76
Quick Ratio
5.53
Current Ratio
5.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-40.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-77.78%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-43%
ROE
-47%
ROC
-0.53%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.01-0.035
52W High
-
52W Low
-
RSI
-
Rel Volume
0.08
Avg Volume
55.45K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-3.581
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
ABEC.DE
LLY.DE
GOOGL
AVGO
0YXG.L
Same Sector
KNB.L
2005.HK
0J8Z.L
ICCC
SNDX
Check Those
PHIA.AS
TFA.BR
CIVIX
RALLIS.NS
ALBOA.PA
Similar Market Cap
ALVET.PA
ASP.TO
FAIL
MLPRX.PA
VRS.L

Company Profile

Healthcare Biotechnology
  • Volume Average 55.45K
  • Market Capitalization 2.05M
  • CEO Mr. David Goren
  • Headquarters Toronto,ON,CA
  • IPO Date 2010-03-30
  • Website https://www.vaxil-bio.com

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.